医学
PD-L1
程序性细胞死亡1
肿瘤科
内科学
彭布罗利珠单抗
重症监护医学
作者
Shaodong Hong,Zhihuang Hu,Jin Sheng,Xuanye Zhang,Sha Fu,Yuhong Wang,Wei Liang,Wenfeng Fang,Li Zhang
标识
DOI:10.1200/jco.2018.36.15_suppl.e18503
摘要
e18503Background: Currently, no PD-1/PD-L1 inhibitors have been approved by the Chinese FDA. Such care disparities definitely limit the therapeutic opportunities of Chinese cancer patients. We cond...
科研通智能强力驱动
Strongly Powered by AbleSci AI